B. Riley Wealth Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

B. Riley Wealth Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-833	Closed	-$249K	–	862
2019 Q2	$249K	Sell	833 -417	-33%	-$174K	0.03%	638
2019 Q1	$563K	Sell	1,250 -139	-10%	-$60.8K	0.07%	300
2018 Q4	$635K	Hold	1,389	–	–	0.09%	240
2018 Q3	$1.26M	Hold	1,389	–	–	0.15%	151
2018 Q2	$815K	Hold	1,389	–	–	0.11%	207
2018 Q1	$905K	Buy	+1,389	New	+$1.04M	0.13%	185

Other funds holding HTGM

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

B. Riley Wealth Advisors's HTGM Position: Q3 2019 in Review

B. Riley Wealth Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2019, closing a stake of 833 shares — an estimated $249K sold.

B. Riley Wealth Advisors first reported a position in HTGM in Q1 2018 and held it in 6 quarters. The position peaked at $1.26M in Q3 2018. 44 funds tracked by Wall St. Rank hold HTGM as of Q3 2019.

B. Riley Wealth Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
B. Riley Wealth Advisors sold 833 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2019, an estimated $249K.
B. Riley Wealth Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 6 quarters.
B. Riley Wealth Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $1.26M in Q3 2018.
44 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2019.

Based on B. Riley Wealth Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.